Page 320«..1020..319320321322..330340..»

Drug Discovery Services Market is Expected to Witness Significant Growth between 20212031 – BioSpace

Posted: July 27, 2022 at 2:25 am

Wilmington, Delaware, United States, Transparency Market Research Inc.: The drug discovery services market has been projected to grow at a noteworthy pace in the foreseeable years. The rapid growth in the market is attributed to the increasing demand for a constant process for the discovery of drugs due to the unmet need for disease biology.

Read Report Overview - https://www.transparencymarketresearch.com/drug-discovery-services-market.html

Healthcare providers and patients across the globe are in the pursuit of novel therapies, for instance, drugs with safety and efficacy profiles. These factors are further estimated to create revenue generation opportunities in the drug discovery services market in the coming years.

The service providers in the market are strengthening their strength in platforms and target. The companies serving in the pharma and biopharma market are likely to experience massive revenue potential in screening assays and pharmacology studies. In addition to this, the demand for the services related to integrated drug discovery, starting from drug identification procedures is expected to serve as revenue generator in the drug discovery services market.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=52656

Drug Discovery Services Market: Key Trends

In recent years, there has been a noteworthy increase in the count of contract research organizations in emerging economies. This factor is likely to prove cost-effective for the innovators who are working in the pharma companies. Further, the growing requirement for effective formulation strategies for preclinical studies has been projected to set a tone for innovations across the market. These factors are further predicted to increase sales avenues in the drug discovery services market during the forecast period.

Drug discovery has been referred to as the procedure to identify and develop a compound that comes with pharmacological activity. It is a useful process to treat disease. The discovery of drugs has been a lengthy and complex process that requires a lot of stages for production. In addition to this, the process needs to be safe, efficacious, and hold regulatory compliance. There are significant changes that are taking place in the field of drug discovery and informatics along with the rising adoption of numerous computational methods that assist the candidates. These factors are further likely to bolster expansion opportunities in the drug discovery services market.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=52656

Drug Discovery Services Market: Competitive Dynamics and Key Developments

Owing to nature, the drug discovery services market has been highly fragmented. Further, the prominent players serving in the market are incorporating novel initiatives to generate novel expansion opportunities in the industry. These players also focus to adopt numerous growth strategies. The growth strategies in the market include product upgrades, expansion of the companys footprints globally, mergers and acquisitions, portfolio diversion, expansion of the product or service distribution network, and novel product launching. In addition to these initiatives, there has been a noticeable increase in the investment by the industry players in numerous R & D activities to provide effective and improved services to end-users.

The key players in the drug discovery services market are:

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=52656

Drug Discovery Services Market: Regional Assessment

The drug discovery services market has been classified into Europe, the Middle East & Africa, North America, Asia Pacific, and Latin America. Out of these regional areas, Europe and North America have been predicted to hold a dominating position in the market. The rapid growth in these regions has been attributed to the advanced healthcare infrastructure. In addition to this, traditional drug development along with testing and scrutiny of approval procedures are some noteworthy problems not only for patients but also for the drug industry who have been waiting for novel drugs against illnesses. These factors are further likely to create expansion opportunities in the drug discovery services market in the upcoming years.

Increasing government initiatives, rising cases of infectious diseases, and a large population base are some factors that are likely to bolster growth opportunities in the Asia Pacific region.

More Trending Reports by Transparency Market Research

Bioanalytical Testing Services Market: Rise in demand for biopharma products and increasing clinical use of biosimilars for different indications are some key factors fuelling the growth of bioanalytical testing services market.

Equine Healthcare Market: The global equine healthcare market is expected to cross the value of US$ 972.8 Mn by the end of 2028.

Stem Cells Market: The global stem cells market is expected to reach the value of US$ 25.68 Bn by the end of 2028.

Medical Imaging Equipment Market: The global medical imaging equipment market is expected to reach the value of US$ 50.3 Bn by the end of 2028.

Home Healthcare Market: The global home healthcare market is expected to reach the value of US$ 499.6 Bn by the end of 2028.

Triclabendazole Market: The global triclabendazole market is expected to reach the value of US$ 632.1 Mn by the end of 2031.

Anti-aging Market: The global anti-aging market is expected to surpass the value of US$ 284.8 Bn by the end of 2028.

Brucellosis Vaccine Market: Rise in prevalence of brucellosis and increase in awareness among people are projected to drive the global brucellosis vaccine market during the forecast period.

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

Originally posted here:
Drug Discovery Services Market is Expected to Witness Significant Growth between 20212031 - BioSpace

Posted in Delaware Stem Cells | Comments Off on Drug Discovery Services Market is Expected to Witness Significant Growth between 20212031 – BioSpace

Stem Cells Market to Expand at a CAGR of 10.4% from 2021 to 2028 Travel Adventure Cinema – Travel Adventure Cinema

Posted: July 27, 2022 at 2:25 am

Stem Cells Market: Introduction

According to the report, the globalstem cells marketwas valued at US$11.73Bn in 2020 and is projected to expand at a CAGR of10.4%from 2021 to 2028. Stem cells are defined as specialized cells of the human body that can develop into various different kinds of cells. Stem cells can form muscle cells, brain cells and all other cells in the body. Stem cells are used to treat various illnesses in the body.

North America was the largest market for stem cells in 2020. The region dominated the global market due to substantial investments in the field, impressive economic growth, increase in incidence of target chronic diseases, and technological progress. Moreover, technological advancements, increase in access to healthcare services, and entry of new manufacturers are the other factors likely to fuel the growth of the market in North America during the forecast period.

Request A Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

Asia Pacific is projected to be a highly lucrative market for stem cells during the forecast period. The market in the region is anticipated to expand at a high CAGR during the forecast period. High per capita income has increased the consumption of diagnostic and therapy products in the region. Rapid expansion of the market in the region can be attributed to numerous government initiatives undertaken to improve the health care infrastructure. The market in Asia Pacific is estimated to expand rapidly compared to other regions due to shift in base of pharmaceutical companies and clinical research industries from developed to developing regions such as China and India. Moreover, changing lifestyles and increase in urbanization in these countries have led to a gradual escalation in the incidence of lifestyle-related diseases such as cancer, diabetes, and heart diseases.

Technological Advancements to Drive Market

Several companies are developing new approaches to culturing or utilizing stem cells for various applications. Stem cell technology is a rapidly developing field that combines the efforts of cell biologists, geneticists, and clinicians, and offers hope of effective treatment for various malignant and non-malignant diseases. The stem cell technology is progressing as a result of multidisciplinary effort, and advances in this technology have stimulated a rapid growth in the understanding of embryonic and postnatal neural development.

Adult Stem Cells Segment to Dominate Global Market

In terms of product type, the global stem cells market has been classified into adult stem cells, human embryonic stem cells, and induced pluripotent stem cells. The adult stem cells segment accounted for leading share of the global market in 2020. The capability of adult stem cells to generate a large number of specialized cells lowers the risk of rejection and enables repair of damaged tissues.

Request Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=132

Autologous Segment to Lead Market

Based on source, the global stem cells market has been bifurcated into autologous and allogenic. The autologous segment accounted for leading share of the global market in 2020. Autologous stem cells are used from ones own body to replace damaged bone marrow and hence it is safer and is commonly being practiced.

Regenerative Medicines to be Highly Lucrative

In terms of application, the global stem cells market has been categorized into regenerative medicines (neurology, oncology, cardiology, and others) and drug discovery & development. The regenerative medicines segment accounted for major share of the global market in 2020, as regenerative medicine is a stem cell therapy and the medicines are made using stem cells in order to repair an injured tissue. Increase in the number of cardiac diseases and other health conditions drive the segment.

Therapeutics Companies Emerge as Major End-users

Based on end-user, the global stem cells market has been divided into therapeutics companies, cell & tissue banks, tools & reagents companies, and service companies. The therapeutics companies segment dominated the global stem cells market in 2020. The segment is driven by increase in usage of stem cells to treat various illnesses in the body. Therapeutic companies are increasing the utilization of stem cells for providing various therapies. However, the cell & tissue banks segment is projected to expand at a high CAGR during the forecast period. Increase in number of banks that carry out research on stem cells required for tissue & cell growth and elaborative use of stem cells to grow various cells & tissues can be attributed to the growth of the segment.

Regional Analysis

In terms of region, the global stem cells market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global stem cells market in 2020, followed by Europe. Emerging markets in Asia Pacific hold immense growth potential due to increase in income levels in emerging markets such as India and China leading to a rise in healthcare spending.

Request for covid19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=132

Competition Landscape

The global stem cells market is fragmented in terms of number of players. Key players in the global market include STEMCELL Technologies, Inc., Astellas Pharma, Inc., Cellular Engineering Technologies, Inc., BioTime, Inc., Takara Bio, Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics, Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

Stem Cells Market, by Application

Stem Cells Market, by End-user

More Trending Reports by Transparency Market Research:

Animal Health Care Market: https://www.transparencymarketresearch.com/india-animal-health-care-market.html

Albumin Market: https://www.transparencymarketresearch.com/global-albumin-market.html

Veterinary Therapeutics Market: https://www.transparencymarketresearch.com/ksa-veterinary-therapeutics-market.html

Geriatric Care Services Market: https://www.transparencymarketresearch.com/geriatric-care-services-market.html

Gene Therapy Market: https://www.transparencymarketresearch.com/gene-therapy-market.html

Malaysia Medical Tourism Market: https://www.transparencymarketresearch.com/malaysia-medical-tourism-market.html

Pulmonary Arterial Hypertension (PAH) Market: https://www.transparencymarketresearch.com/pulmonary-arterial-hypertension-therapeutics.html

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets.The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website:https://www.transparencymarketresearch.comBlog:https://tmrblog.comEmail:%5Bemailprotected%5D

Read the original here:
Stem Cells Market to Expand at a CAGR of 10.4% from 2021 to 2028 Travel Adventure Cinema - Travel Adventure Cinema

Posted in Delaware Stem Cells | Comments Off on Stem Cells Market to Expand at a CAGR of 10.4% from 2021 to 2028 Travel Adventure Cinema – Travel Adventure Cinema

Dental Membrane and Bone Graft Substitutes Market to Exceed Value of US$ 1,337 Mn by 2031 – PR Newswire UK

Posted: July 27, 2022 at 2:25 am

WILMINGTON, Del., July 21, 2022 /PRNewswire/ --An in-depth demand analysis of dental membrane and bone graft substitutes found that massive demand for resorbable bone grafting materials presents value-grab opportunity. Companies in the dental membrane and bone graft substitutes market are actively leaning on development of novel biomaterials to meet the needs of bone grafting procedures. The TMR study projects the size of the market to surpass worth of US$ 1,337 Mn by 2031.

Advancements in periodontology are catalyzing introduction of new soft tissue regeneration, as emerging trends of the dental membrane and bone graft substitutes market underscore. Moreover, dental membrane and bone graft substitutes market projections in the TMR study have found that the use of xenograft for dental bone regeneration is anticipated to rise rapidly, and will unlock lucrative avenues. The fact that xenografts are cost-effective and show good results in bone tissue regeneration will spur the popularity of products in the segment.

Increasing number of bone regeneration procedures has led to the commercialization of novel biomaterials and dental bone grafts. The application of human cell sources in bone graft substitutes is growing, thus extending the canvas for companies in the dental membrane and bone graft substitutes market. Rise in oral disorders and injuries has impelled the need for bone substitute materials that can promise long-term survival rates in the patients.

Request Brochure of Dental Membrane and Bone Graft Substitutes Market Research Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16340

Key Findings of Dental Membrane and Bone Graft Substitutes Market Study

Request for Analysis of COVID-19 Impact on Dental Membrane and Bone Graft Substitutes Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=16340

Dental Membrane and Bone Graft Substitutes Market: Key Drivers

Dental Membrane and Bone Graft Substitutes Market: Regional Growth Dynamics

Get Exclusive PDF Sample Copy of Dental Membrane and Bone Graft Substitutes Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16340

Dental Membrane and Bone Graft Substitutes Market: Key Players

High degree of fragmentation has characterized the competition landscape in the dental membrane and bone graft substitutes market, mainly due to presence of several prominent players. Some of the key players are Zimmer Biomet, OPKO Health, Inc., NovaBone Products, LLC., Nobel Biocare Services AG, Geistlich Pharma AG, Dentsply Sirona, Collagen Matrix, Inc., BioHorizons, and Institut Straumann AG.

Make an Enquiry Before Buying https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=16340

Dental Membrane and Bone Graft Substitutes Market Segmentation

Regions Covered

Countries

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated withLatest Healthcare Research Reportsby Transparency Market Research:

Non-Invasive Prenatal Testing Market: Non-invasive prenatal testing market was worth around US$ 1.3 Bn in 2018. The market is likely to develop at a CAGR of 16.4% during the forecast period, from 2019 to 2027.

Cell Culture Media, Sera, and Reagents Market: The global cell culture media, sera, and reagents market is majorly driven by growth and expansion of biotechnology & pharmaceutical companies and academic & research institutes.

Stem Cells Market: The global stem cells market is majorly driven by rising applications of stem cells in regenerative medicines. Increase in the number of chronic diseases such as cardiac diseases, diabetes, cancer, etc.

Cell Line Authentication and Characterization Tests Market: Increase in the geriatric population and surge in incidence of chronic diseases are projected to drive the global cell line authentication and characterization tests market.

CAR T-cell Therapy Market: The CAR T-cell therapy market is expected to clock a CAGR of 30.6% during the assessment period. The CAR T-cell therapy is known as a revolutionary treatment option for cancer, owing to its remarkably effective and durable clinical responses.

Cell & Tissue Preservation Market: Rise in investments in the field of regenerative medicine research is estimated to propel the market. Human blood, tissues, cells, and organs own the capability to heal damaged tissues and organs with long-term advantages.

mHealth Monitoring Diagnostic Medical Devices Market: The global mHealth monitoring diagnostic medical devices market was valued at US$ 29.05 Bn in 2018 and is projected to expand at a CAGR of 20.5% from 2019 to 2027.

Pediatric Medical Devices Market: The global pediatric medical devices market was valued at US$ 21,000 Mn in 2017 and is projected to expand at a CAGR of 8.0% from 2018 to 2026.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update -https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact :Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website:https://www.transparencymarketresearch.comBlog:https://tmrblog.comEmail:sales@transparencymarketresearch.com

Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

SOURCE Transparency Market Research

See the original post here:
Dental Membrane and Bone Graft Substitutes Market to Exceed Value of US$ 1,337 Mn by 2031 - PR Newswire UK

Posted in Delaware Stem Cells | Comments Off on Dental Membrane and Bone Graft Substitutes Market to Exceed Value of US$ 1,337 Mn by 2031 – PR Newswire UK

Lipid Disorder Treatment Market is Projected to Experience Promising Growth Opportunities in the Forthcoming Years – BioSpace

Posted: July 27, 2022 at 2:25 am

Wilmington, Delaware, United States, Transparency Market Research Inc.: Emergence of various lifestyle diseases has been witnessed worldwide, especially among teens and people lying in the 50-60 years age group. Lipid disorders are largely caused due to high cholesterol and triglycerides, which ultimately can result in increased chances of heart diseases, which has prompted the development of safe and efficient treatments for lipid disorders. Moreover, smoking and drinking have largely contributed to the rising prevalence of lipid disorders and other cardiovascular diseases among men and women. This has fuelled demand for advanced treatments such as introduction of modern lipid lowering drugs. The demand for lipid disorder treatments has risen owing to occupational diseases caused by higher consumption of alcohol results in rising amount of bad cholesterol or LDL, irregular eating habits, lack of body exercises and improper medication.

Read Report Overview - https://www.transparencymarketresearch.com/lipid-disorder-treatment-market.html

Analysis of Transparency Market Research shows that the global market for lipid disorder treatment is expected to grow at an exceptional pace during the period of assessment. This growth is fuelled by rising demand for modern lipid metabolism disorder treatments coupled with increased chances of cardiovascular diseases across the globe. The global market for lipid disorder treatment is poised to register a value CAGR of 7.4% during the period of assessment, 2017-2026.

Several biopharma companies are focusing on developing effective solutions for treating lipid disorders. Companies involved in lipid disorder treatment market include Teva Pharmaceuticals, Mylan Pharmaceuticals, Inc., Kowa Pharmaceuticals America, Inc., Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., and Wockhardt Limited.

Request Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=40640

Sales of Drugs to Treat Lipid Disorders to Remain High in North America

United States has registered a higher number of people acquiring lipid disorders, especially among adults. Growing consumption of drugs such as atorvastatin and fluvastatin to treat hypercholesterolemia and other associated lipid disorders has been witnessed in the country. Several tests have been performed to identify patients who have a high risk of developing lipid disorders owing to family history or genetic disorders. According to American Academy of Pediatrics and National Heart, Lung and Blood Institute, atherosclerotic cardiovascular disease is a leading cause of death in the region.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40640

This has pushed the use of prescription drugs in the region, making it imperative for pharma companies to increase their production rate and revise their production cycles. In addition, screening for lipid disorders in childhood has been initiated in the region, and as per study, a moderate percentage of children population in the United States is being affected by lipid disorders, that typically surface as the child reaches its teenage. This has presented potential opportunities for sale of drugs for the treatment of lipid disorders in North America, making it an attractive region from a business point of view.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=40640

Atorvastatin to Witness Increased Demand for Lipid Disorder Treatment

As the risk of developing lipid disorders increases, pharmaceutical companies have initiated drug enhancement, introduction of new drugs and conducting phase trials of these drugs on a large scale. Statins are considered to be highly effective in lowering the rate cardiovascular events. Most companies are focusing on mass production of atorvastatin as they are a highly effective low density lipoprotein lowering agents, LDL being the main cause of lipid disorders and associated heart diseases. The consumption of atorvastatin is expected to grow at a higher rate. Market for atorvastatin is poised to reach a value of over US$ 16 Bn by the end of the assessment period.

More Trending Reports by Transparency Market Research:

Glioma Treatment Market- Glioma is a condition that covers a broad category of brain and spinal cord tumors that affect the glial cells in the brain. Glioma can affect brain function and can be fatal depending on its location and severity of the tumor. Different types of gliomas are astrocytoma, brain stem gliomas, ependymomas, mixed gliomas (oligo-astrocytomas), oligodendrogliomas, and optic pathway gliomas.

Anticoagulant Reversal Drug Market- Substantial use of vitamin K for reversal of warfarin anticoagulation therapy is creating ample opportunities in anticoagulant reversal drugs market. Significant demand for anticoagulant reversal drugs for the growing number of warfarin therapy administered for blood clotting due to accidents, medical conditions fuels the growth of anticoagulant reversal drugs market.

Point-of-Care (POC) Coagulation Testing Devices Market- Coagulation, or clotting, is the process of conversion of liquid blood into a gel-like clot to stop bleeding. The capability of the body cells to prevent blood loss after a vascular injury by forming a blood clot is vital to sustaining health.

Bioanalytical Testing Services Market- Rise in demand for biopharma products and increase in need to develop novel bioanalytical assay platforms are the key factors driving investments in bioanalytical R&D and laboratories. Increase in trend of outsourcing laboratory testing services for quality check has encouraged companies to offer various types of services and solutions in the market.

Life Care Solution Services Market- The global life care solution services market is projected to grow due to technological advancements in health care solutions & services, surge in R&D funding, increase in demand for surgeries, and rise in prevalence of chronic diseases.Clinical Decision Support System Market Analysis Report 2031

Bone Growth Stimulators Market- Bone growth stimulator provides painless electrical or ultrasound stimulation, which promotes bone growth and facilitates faster bone healing. Several orthopedic surgeons recommend this device in patients with history of smoking.

Behavioral Health Market- Behavioral health services comprise mental health, alcohol & substance abuse, depression, anxiety, post-traumatic stress disorder, schizophrenia, and eating disorder services. Rise in number of adults, children, and elderly people with serious mental illness has increased the need for behavioral health treatment.

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

Read this article:
Lipid Disorder Treatment Market is Projected to Experience Promising Growth Opportunities in the Forthcoming Years - BioSpace

Posted in Delaware Stem Cells | Comments Off on Lipid Disorder Treatment Market is Projected to Experience Promising Growth Opportunities in the Forthcoming Years – BioSpace

Kiwis with multiple sclerosis patients thriving from overseas stem-cell treatment urge Government to approve it here – Newshub

Posted: July 27, 2022 at 2:24 am

The Government's being urged to get a move on and approve a stem-cell treatment for people with multiple sclerosis (MS).

A petition was presented to Parliament on Tuesday, calling for the Health Minister to fund the treatment which has shown to halt some of the debilitating symptoms of the disease.

Three years ago Anne Besley never thought she'd be standing outside Parliament with her mum. She was in constant pain and could barely walk.

"I'm not on drugs anymore, I'm able to work part-time. I hardly ever need the crutches and there are days when I have to think hard about do I actually have MS," Besley said.

"It's all thanks to a self-funded trip to India in 2019 for expensive stem-cell treatment."

It was treatment that allowed Besley to get her life back.

That same year Wellingtonian Karyn Bishop spent more than $120,000 getting the same treatment in Russia.

She couldn't walk unaided before she left, but a year later she managed a kilometre walk around a park.

"There's so many people that miss out on it because they simply can't afford it. We're spending thousands on drugs that only work for a certain percentage of people and this treatment has been shown to work."

The treatment works by harvesting stem cells from the patient's bone marrow.

Chemotherapy is given to shut down the faulty immune system before the stem cells are put back in to grow a new immune system.

But at present it's only available for blood cancer patients.

On Tuesday the ACT Party accepted a petition with 10,000 signatures urging the Government to extend the treatment to MS.

"I would like to see more forward planning in New Zealand about the newer medicines that we are falling behind the rest of the world on," said ACT's deputy leader Brooke van Velden.

Green Party MP Golriz Ghahraman, who has MS, said it's a no-brainer.

"It is concerning to me that people are having to buy this medicine, essential medicine, on the free market. We have a healthcare system."

Health Minister Andrew Little acknowledged the treatment shows positive results but said it is up to the drug-buying agency Pharmac to decide what drugs are funded.

Visit link:
Kiwis with multiple sclerosis patients thriving from overseas stem-cell treatment urge Government to approve it here - Newshub

Posted in Cell Medicine | Comments Off on Kiwis with multiple sclerosis patients thriving from overseas stem-cell treatment urge Government to approve it here – Newshub

MHRA grants marketing authorisation to Global Blood Therapeutics for sickle cell disease drug – PMLiVE

Posted: July 27, 2022 at 2:23 am

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted Global Blood Therapeutics (GBT) a British marketing authorisation for Oxbryta also known as voxelotor for both adult and paediatric patients 12 years of age and older requiring treatment of haemolytic anaemia due to sickle cell disease (SCD).

The authorisation supports the use of Oxbryta as either a monotherapy or for use in combination with hydroxycarbamide, also known as hydroxyurea.

Oxbryta is an oral treatment taken once daily and is the first medicine authorised in Britain that directly blocks sickle haemoglobin (HbS) polymerisation, which is the molecular foundation of sickling and the destruction of red blood cells in SCD.

In the UK, approximately 15,000 people are affected by SCD, a progressive and complex condition which can cause serious complications, including organ damage. For those living with the condition, it is common to experience economic disadvantages and health inequalities as SCD can inflict negative societal impacts in areas like healthcare, education and employment.

Beginning in early childhood, SCD complications can include neurocognitive impairment, acute chest syndrome and silent and overt stroke. It has been shown that early intervention and treatment of SCD can potentially change the course of this disease and, in turn, reduce symptoms and events while preventing long-term organ damage and extending life expectancy.

The marketing authorisation from the MHRA follows the European Commission (EC) authorisation which was made earlier this year and is based on data taken from the phase 3 HOPE trial. The results demonstrated clinically meaningful and statistically significant improvements in haemoglobin (Hb) levels, accompanied by a reduction of haemolysis markers, for patients treated with Oxbryta.

In 2021, Oxbryta was the first SCD treatment to be granted a Promising Innovative Medicine (PIM) designation from the MHRA, which then allowed the medicine to receive a positive scientific opinion under the Early Access to Medicines Scheme (EAMS). Healthcare professionals were then able to treat selected patients with Oxbryta ahead of market authorisation, based on clinical factors to address a clear unmet medical need.

Dr Beatriz Pujol, vice president, head of medical affairs EU & GCC at GBT, said: Following this marketing authorisation by the MHRA, we look forward to working with the National Institute of Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) with the goal of helping to facilitate rapid access to voxelotor for people living with sickle cell disease who may benefit from this important treatment.

Link:
MHRA grants marketing authorisation to Global Blood Therapeutics for sickle cell disease drug - PMLiVE

Posted in Cell Medicine | Comments Off on MHRA grants marketing authorisation to Global Blood Therapeutics for sickle cell disease drug – PMLiVE

CAR T-Cell Therapy Turns 10 and Finally Earns the Word ‘Cure’ – Medscape

Posted: July 27, 2022 at 2:23 am

Ten years ago, Stephan Grupp, MD, PhD, plunged into an unexplored area of pediatric cancer treatment with a 6-year-old patient for whom every treatment available for her acute lymphoblastic leukemia (ALL) had been exhausted.

Dr Stephan Grupp

Grupp, a pioneer in cellular immunotherapy at Children's Hospital of Philadelphia (CHOP), had just got the green light to launch the first phase 1 trial of chimeric antigen receptor (CAR) T-cell therapy for children.

"The trial opened at the absolute last possible moment that it could have been helpful to her," he told Medscape Medical News. "There was nothing else to do to temporize her further.... It had to open then or never."

The patient was Emily Whitehead, who has since become a poster girl for the dramatic results that can be achieved with these novel therapies. After that one CAR T-cell treatment back in 2012, she has been free of her leukemia and has remained in remission for more than 10 years.

Grupp says that he is, at last, starting to use the "cure" word.

"I'm not just a doctor, I'm a scientist and one case isn't enough to have confidence about anything," he said. "We wanted more patients to be out longer to be able to say that thing which we have for a long time called the 'c word.'

"CAR T-cell therapy has now been given to hundreds of patients at CHOP, and we are unique in this we have a couple dozen patients who are 5, 6, 7, 9 years out or more without further therapy. That feels like a cure to me," he commented.

Emily was the first patient with ALL to receive the novel treatment, and also the first child.

There wasaprecedent, however. After having been "stuck" for decades, the CAR T-cell field had recently made a breakthrough, thanks to research by Grupp's colleague Carl June and his team at the University of Pennsylvania. By tweaking two key steps in the genetic modification of T cells, June's team had successfully treated three adults with chronic lymphocytic leukemia (CLL), two of whom were in complete remission.

But using the treatment for a child and for a different type of leukemia was a daunting prospect. Grupp recalls that he was candidwith Emily's parents, Tom and Kari Whitehead, emphasizing that there are no guarantees in cancer treatment, particularly in a phase 1 trial.

But the Whiteheads had no time to waste and nowhere else to turn. Her father, Tom, recalls saying: "This is something outside the box, this is going to give her a chance."

Grupp, who describes himself as being "on the cowboy end" of oncology care, was ready to take the plunge.

Little did any of them know that the treatment would make Emily even sicker than she already was, putting her in intensive care. But thanks to a combination of several lucky breaks and a lot of brain power, she would make a breathtakingly rapid recovery.

CAR T-cell therapy involves harvesting a patient's T cells and modifying them in the lab with a chimeric antigen receptor to target CD19, a protein found on the surface of ALL cancer cells.

Before the University of Pennsylvania team tweaked the process, clinical trials of the therapy yielded only modest results because the modified T cells "were very powerful in the short term but had almost no proliferative capacity" once they were infused back into the patient, Grupp explained.

"It does not matter how many cells you give to a patient, what matters is that the cells grow in the patient to the level needed to control the leukemia," he said.

June's team came up with what Grupp calls "the magic formula": a bead-based manufacturing process that produced younger T-cell phenotypes with "enormous" proliferative capacity, and a lentiviral approach to the genetic modification, enabling prolonged expression of the CAR-T molecule.

"Was it rogue? Absolutely, positively not," said Grupp, thinking back to the day he enrolled Emily in the trial. "Was it risky? Obviously...we all dived into this pool without knowing what was under the water, so I would say, rogue, no, risky, yes. And I would say we didn't know nearly enough about the risks."

The gravest risk that Grupp and his team encountered was something they had not anticipated. At the time, they had no name for it.

The three adults with CLL who had received CAR T-cell therapy had experienced a mild version that the researchers referred to as "tumor lysis syndrome" (N Engl J Med. 2011;365:725-33).

But for Emily, on day 3 of her CAR T-cell infusion, there was a ferocious reaction storm that later came to be called cytokine release syndrome (CRS).

"The wheels just came off then," said Tom. "I remember her blood pressure was 53 over 29. They took her to the ICU, induced a coma, and put her on a ventilator. It was brutal to watch. The oscillatory ventilator just pounds on you, and there was blood bubbling out around the hose in her mouth.

"I remember the third or fourth night, a doctor took me in the hallway and said, 'There's a one-in-a-thousand chance your daughter is alive when the sun comes up,' " Tom told Medscape Medical News. "And I said, 'Alright, I'll see you at rounds tomorrow, because she'll still be here.' "

"We had some vague notion of toxicity...but it turned out not nearly enough," said Grupp. The ICU "worked flat out" to save her life, he recalls. "They had deployed everything they had to keep a human being alive and they had nothing more to add. At some point, you run out of things that you can do, and we had run out."

It was then that the team ran into some good luck. The first break was when they decided to look at her cytokines. "Our whole knowledge base came together in the moment, on the fly, at the exact moment when Emily was so very sick," he recalls. "Could we get the result fast enough? The lab dropped everything to run the test."

They ordered a broad cytokine panel that included 30 analytes. The results showed that a number of cytokines "were just unbelievably elevated," he said. Among them was interleukin-6 (IL-6).

"IL-6 isn't even made by T cells, so nobody in the world would have guessed that this would have mattered. If we'd ordered a smaller panel, it might not even have been on it. Yet this was the one cytokine we had a drug for tocilizumab so that was chance. And then, another chance was that the drug was at the hospital, because there are rheumatology patients who get it.

"So, we went from making the determination that IL-6 was high and figuring out there was a drug for it at 3:00 o'clock to giving the drug to her at 8:00 o'clock, and then her clinical situation turned around so quickly I mean hours later."

Emily woke up from a 14-day medically induced coma on her seventh birthday.

Eight days later, her bone marrow showed complete remission. "The doctors said, 'We've never seen anyone this sick get better any faster,' " said Tom.

She had already been through a battery of treatments for her leukemia. "It was 22 months of failed, standard treatment, and then just 23 days after they gave her the first dose of CAR T-cells that she was cancer free," he added.

Now that Emily, 17, has remained in remission for 10 years, Grupp is finally willing to use the word "cure" but it has taken him a long time.

Now, he says, the challenge from the bedside is to keep parents' and patients' expectations realistic about what they see as a miracle cure.

"It's not a miracle. We can get patients into remission 90-plus percent of the time but some patients do relapse and then there are the risks [of the cytokine storm, which can be life-threatening].

"Right now, our experience is that about 12% of patients end up in the ICU, but they hardly ever end up as sick as Emily...because now we're giving the tocilizumab much earlier," Grupp said.

Since their daughter's recovery, Tom and Kari Whitehead have dedicated much of their time to spreading the word about the treatment that saved Emily's life. Tom testified at the US Food and Drug Administration's advisory committee meeting in 2017 when approval was being considered for the CAR T-cell product that Emily received. The product was tisagenlecleucel-T (Novartis); at that meeting, there was a unanimous vote to recommend approval. This was the first CAR T cell to reach the market.

As co-founders of the Emily Whitehead Foundation, Tom and Karis have helped raise more than $2 million to support research in the field, and they travel around the world telling their story to "move this revolution forward."

Despite their fierce belief in the science that saved Emily, they also acknowledge there was luck and faith. Early in their journey, when Emily experienced relapse after her initial treatments, Tom drew comfort from two visions, which he calls "whispers," that guided them through several forks in the road and through tough decisions about Emily's treatment.

Several times he and Kari refused treatment that was offered to Emily, and once they had her discharged against medical advice. "I told Kari she's definitely going to beat her cancer I saw it. I don't know how it's going to happen, but we're going to be in the bone marrow transplant hallway [at CHOP] teaching her to walk again. I know a lot of doctors don't want to hear anything about 'a sign,' or what guided us, but I don't think you have to separate faith and science, I think it takes everything to make something like this to happen."

The key to the CAR T-cell breakthrough that gave rise to Emily's therapy was cell proliferation, and the effect is enduring, beyond all expectations, said Grupp. The modified T cells are still detectable in Emily and other patients in long-term remission.

"The fundamental question is, are the cells still working, or are the patients cured and they don't need them?" said Grupp. "I think it's the latter. The data that we have from several large datasets that we developed with Novartis are that if you get to a year and your minimal residual disease testing both by flow and by next-generation sequencing is negative and you still have B-cell aplasia, the relapse risk is close to zero at that point."

While it's still not clear if and when that risk will ever get to zero, Emily and Grupp have successfully closed the chapter.

"Oncologists have different notions of what the word 'cure' means. If your attitude is you're not cured until you've basically reached the end of your life and you haven't relapsed, well, that's an impossible bar to hit. My attitude is, if your likelihood of having a disease recurrence is lower than the other risks in your life, like getting into your car and driving to your appointment, then that's what a functional cure looks like," he said.

"I'm probably the doctor that still sees her the most, but honestly, the whole conversation is not about leukemia at all. She has B-cell aplasia, so we have to treat that, and then it's about making sure there's no long-term side effects from the totality of her treatment. Generally, for a patient who's gotten a moderate amount of chemotherapy and CAR T, that should not interfere with fertility. Has any patient in the history of the world ever relapsed more than 5 years out from their therapy? Of course. Is that incredibly rare? Yes, it is. You can be paralyzed by that, or you can compartmentalize it."

Tom, Emily, and Kate Whitehead

As for the Whiteheads, they are focused on Emily's college applications, her new driver's license, and her project to co-write a film about her story with a Hollywood filmmaker.

Tom says the one thing he hopes clinicians take away from their story is that sometimes a parent's instinct transcends science.

Kate Johnson is a Montreal-based freelance medical journalist who has been writing for more than 30 years about all areas of medicine.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.

Read the original:
CAR T-Cell Therapy Turns 10 and Finally Earns the Word 'Cure' - Medscape

Posted in Cell Medicine | Comments Off on CAR T-Cell Therapy Turns 10 and Finally Earns the Word ‘Cure’ – Medscape

Oncology Peer Review On-The-Go: The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced NonSmall Cell Lung Cancer Treated…

Posted: July 27, 2022 at 2:23 am

Kira MacDougall, MD, and Muhammad Rafay Khan Niazi, MD, spoke with CancerNetwork about their research into the significance of peripheral blood biomarkers of response to immunotherapy in nonsmall cell lung cancer published in the journal ONCOLOGY.

Kira MacDougall, MD, a first year fellow at the University of Oklahoma, and Muhammad Rafay Khan Niazi, MD, a third year resident of Internal Medicine at Staten Island University Hospital, spoke with CancerNetwork about research published in the journal ONCOLOGY titled, The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced NonSmall Cell Lung Cancer Treated With Pembrolizumab: A Clinical Study.

MacDougall and Niazi discuss the clinical utility of absolute lymphocyte count (ALC) and the ratio of absolute neutrophil count to ALC for predicting outcomes with pembrolizumab (Keytruda) in advanced nonsmall cell lung cancer. They also talked about future research in the space and what unanswered questions remain in this treatment setting.

Dont forget to subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

See the original post here:
Oncology Peer Review On-The-Go: The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced NonSmall Cell Lung Cancer Treated...

Posted in Cell Medicine | Comments Off on Oncology Peer Review On-The-Go: The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced NonSmall Cell Lung Cancer Treated…

CRISPR therapeutics can damage the genome – EurekAlert

Posted: July 27, 2022 at 2:23 am

image:Chromosome segregation In dividing cells. Cell cytoskeleton is depicted in red, DNA is depicted in blue and a protein that marks dividing cells is depicted in green. view more

Credit: Tom Winkler, Ben David lab.

The researchers caution: "The CRISPR genome editing method is very effective, but not always safe. Sometimes cleaved chromosomes do not recover and genomic stability is compromised which in the long run might promote cancer."

A new study from TAU identifies risks in the use of CRISPR therapeutics an innovative, Nobel-prize-winning method that involves cleaving and editing DNA, already employed for the treatment of conditions like cancer, liver and intestinal diseases, and genetic syndromes. Investigating the impact of this technology on T-cells white blood cells of the immune system, the researchers detected a loss of genetic material in a significant percentage up to 10% of the treated cells. They explain that such loss can lead to destabilization of the genome, which might cause cancer.

The study was led by Dr. Adi Barzel from the School of Neurobiology, Biochemistry and Biophysics at TAU's Wise Faculty of Life Sciences and Dotan Center for Advanced Therapies, a collaboration between the Tel Aviv Sourasky Medical Center (Ichilov) and Tel Aviv University, and by Dr. Asaf Madi and Dr. Uri Ben-David from TAU's Faculty of Medicine and Edmond J. Safra Center for Bioinformatics. The findings were published in the leading scientific journal Nature Biotechnology.

The researchers explain that CRISPR is a groundbreaking technology for editing DNA cleaving DNA sequences at certain locations in order to delete unwanted segments, or alternately repair or insert beneficial segments. Developed about a decade ago, the technology has already proved impressively effective in treating a range of diseases cancer, liver diseases, genetic syndromes, and more. The first approved clinical trial ever to use CRISPR, was conducted in 2020 at the University of Pennsylvania, when researchers applied the method to T-cells white blood cells of the immune system. Taking T-cells from a donor, they expressed an engineered receptor targeting cancer cells, while using CRISPR to destroy genes coding for the original receptor which otherwise might have caused the T-cells to attack cells in the recipient's body.

In the present study, the researchers sought to examine whether the potential benefits of CRISPR therapeutics might be offset by risks resulting from the cleavage itself, assuming that broken DNA is not always able to recover.

Dr. Ben-David and his research associate Eli Reuveni explain: "The genome in our cells often breaks due to natural causes, but usually it is able to repair itself, with no harm done. Still, sometimes a certain chromosome is unable to bounce back, and large sections, or even the entire chromosome, are lost. Such chromosomal disruptions can destabilize the genome, and we often see this in cancer cells. Thus, CRISPR therapeutics, in which DNA is cleaved intentionally as a means for treating cancer, might, in extreme scenarios, actually promote malignancies."

To examine the extent of potential damage, the researchers repeated the 2020 Pennsylvania experiment, cleaving the T-cells' genome in exactly the same locations chromosomes 2, 7, and 14 (of the human genome's 23 pairs of chromosomes). Using a state-of-the-art technology called single-cell RNA sequencing they analyzed each cell separately and measured the expression levels of each chromosome in every cell.

In this way, a significant loss of genetic material was detected in some of the cells. For example, when Chromosome 14 had been cleaved, about 5% of the cells showed little or no expression of this chromosome. When all chromosomes were cleaved simultaneously, the damage increased, with 9%, 10%, and 3% of the cells unable to repair the break in chromosomes 14, 7, and 2 respectively. The three chromosomes did differ, however, in the extent of the damage they sustained.

Dr. Madi and his student Ella Goldschmidt explain: "Single-cell RNA sequencing and computational analyses enabled us to obtain very precise results. We found that the cause for the difference in damage was the exact place of the cleaving on each of the three chromosomes. Altogether, our findings indicate that over 9% of the T-cells genetically edited with the CRISPR technique had lost a significant amount of genetic material. Such loss can lead to destabilization of the genome, which might promote cancer."

Based on their findings, the researchers caution that extra care should be taken when using CRISPR therapeutics. They also propose alternative, less risky, methods, for specific medical procedures, and recommend further research into two kinds of potential solutions: reducing the production of damaged cells or identifying damaged cells and removing them before the material is administered to the patient.

Dr. Barzel and his PhD student Alessio Nahmad conclude: "Our intention in this study was to shed light on potential risks in the use of CRISPR therapeutics. We did this even though we are aware of the technology's substantial advantages. In fact, in other studies we have developed CRISPR-based treatments, including a promising therapy for AIDS. We have even established two companies one using CRISPR and the other deliberately avoiding this technology. In other words, we advance this highly effective technology, while at the same time cautioning against its potential dangers. This may seem like a contradiction, but as scientists we are quite proud of our approach, because we believe that this is the very essence of science: we don't 'choose sides.' We examine all aspects of an issue, both positive and negative, and look for answers."

Link to the article:

https://www.nature.com/articles/s41587-022-01377-0

Nature Biotechnology

Frequent aneuploidy in primary human T cells after CRISPRCas9 cleavage

30-Jun-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See the article here:
CRISPR therapeutics can damage the genome - EurekAlert

Posted in Cell Medicine | Comments Off on CRISPR therapeutics can damage the genome – EurekAlert

From Donor to Patient: Advancing the Future of Cell Therapies – Genetic Engineering & Biotechnology News

Posted: July 27, 2022 at 2:23 am

Event Date:July 27, 2022Time:11:00 am 3:00 pm ET

Advanced cell therapies continue to be a fantastic success story for both the biotech and life sciences industries, but most importantly for patients who have witnessed first-hand the lifesaving potential of these biotherapeutics. In addition, cell therapies are at the vanguard of many precision medicine initiatives, from off-the-shelf products designed to treat a broad range of patients, to personalized therapeutics that have been engineered to compliment patients genetics. Yet, with all their success comes the challenges that researchers face dailydonor access, scaling manufacturing operations, and safety, to name a few. Understanding the current cell therapy landscape and incorporating the lessons learned from previous successes and failures will allow the industry to keep pushing the limits of whats possible scientifically while helping speed up new safe, efficacious therapies to market.

ThisGENSummit has amassed an extraordinary selection of thought leaders to discuss the latest trends, newest technologies, and practical solutions to common challenges that face organizations devoting their time to cell therapy research. Our summit will kick off with an exciting keynote address fromWilliam Ho,President, CEO, and Co-Founder of IN8bio, which is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. Together, during this half-day conference, we will discover the current state of the cell therapy space and hear about the amazing potential that many novel cell therapies have to truly impact patients lives.

Register now and reserve your spot for what is sure to be an exciting and immensely informative event!

See the original post:
From Donor to Patient: Advancing the Future of Cell Therapies - Genetic Engineering & Biotechnology News

Posted in Cell Medicine | Comments Off on From Donor to Patient: Advancing the Future of Cell Therapies – Genetic Engineering & Biotechnology News

Page 320«..1020..319320321322..330340..»